Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gangliosides are sialylated glycolipids, mainly present at the cell surface membrane, involved in a variety of cellular signaling events. During malignant transformation, the composition of these glycosphingolipids is altered, leading to structural and functional changes, which are often negatively correlated to patient survival. Cancer cells have the ability to shed gangliosides into the tumor microenvironment, where they have a strong impact on anti-tumor immunity and promote tumor progression. Since most ganglioside species show prominent immunosuppressive activities, they might be considered checkpoint molecules released to counteract ongoing immunosurveillance. In this review, we highlight the current state-of-the-art on the ganglioside-mediated immunomodulation, specified for the different immune cells and individual gangliosides. In addition, we address the dual role that certain gangliosides play in the tumor microenvironment. Even though some ganglioside species have been more extensively studied than others, they are proven to contribute to the defense mechanisms of the tumor and should be regarded as promising therapeutic targets for inclusion in future immunotherapy regimens.

          Related collections

          Most cited references143

          • Record: found
          • Abstract: found
          • Article: not found

          Macrophages as regulators of tumour immunity and immunotherapy

          Macrophages are critical mediators of tissue homeostasis, with tumors distorting this proclivity to stimulate proliferation, angiogenesis, and metastasis. This had led to an interest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across therapeutic modalities and tumor types. Much of the observed efficacy can be traced to the suppressive capacity of macrophages, driven by microenvironmental cues such as hypoxia and fibrosis. As a result, tumor macrophages display an ability to suppress T cell recruitment and function as well as regulate other aspects of tumor immunity. With the increasing impact of cancer immunotherapy, macrophage targeting is now being evaluated in this context. Here we will discuss the results of clinical trials and the future of combinatorial immunotherapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Glycosylation in health and disease

            The glycome describes the complete repertoire of glycoconjugates composed of carbohydrate chains, or glycans, that are covalently linked to lipid or protein molecules. Glycoconjugates are formed through a process called glycosylation and can differ in their glycan sequences, the connections between them and their length. Glycoconjugate synthesis is a dynamic process that depends on the local milieu of enzymes, sugar precursors and organelle structures as well as the cell types involved and cellular signals. Studies of rare genetic disorders that affect glycosylation first highlighted the biological importance of the glycome, and technological advances have improved our understanding of its heterogeneity and complexity. Researchers can now routinely assess how the secreted and cell-surface glycomes reflect overall cellular status in health and disease. In fact, changes in glycosylation can modulate inflammatory responses, enable viral immune escape, promote cancer cell metastasis or regulate apoptosis; the composition of the glycome also affects kidney function in health and disease. New insights into the structure and function of the glycome can now be applied to therapy development and could improve our ability to fine-tune immunological responses and inflammation, optimize the performance of therapeutic antibodies and boost immune responses to cancer. These examples illustrate the potential of the emerging field of 'glycomedicine'.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              NK cells and cancer: you can teach innate cells new tricks.

              Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.
                Bookmark

                Author and article information

                Contributors
                s.vanvliet@amsterdamumc.nl
                Journal
                Cancer Metastasis Rev
                Cancer Metastasis Rev
                Cancer Metastasis Reviews
                Springer US (New York )
                0167-7659
                1573-7233
                2 June 2023
                2 June 2023
                2023
                : 42
                : 3
                : 941-958
                Affiliations
                [1 ]GRID grid.12380.38, ISNI 0000 0004 1754 9227, Department of Molecular Cell Biology and Immunology, , Amsterdam UMC location Vrije Universiteit Amsterdam, ; De Boelelaan, 1117 Amsterdam, the Netherlands
                [2 ]Cancer Biology and Immunology, Cancer Center Amsterdam, ( https://ror.org/0286p1c86) Amsterdam, the Netherlands
                [3 ]Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
                Author information
                https://orcid.org/0000-0001-9679-8149
                http://orcid.org/0000-0003-1811-2687
                Article
                10108
                10.1007/s10555-023-10108-z
                10584724
                37266839
                b864378e-baf1-4791-99e7-91a21ff1f5ee
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 23 February 2023
                : 13 May 2023
                Categories
                Non-Thematic Review
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2023

                Oncology & Radiotherapy
                gangliosides,shedding,tumor immunity,glycosylation
                Oncology & Radiotherapy
                gangliosides, shedding, tumor immunity, glycosylation

                Comments

                Comment on this article